Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2024-05-15 Investor Presentation
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Results for the first quarter of 2024
Investor Presentation Classification · 99% confidence The document is explicitly titled "Photocure ASA 1st Quarter 2024 Results" and contains detailed financial tables for Q1 '24 vs Q1 '23, including Consolidated Income Statement and Segment Performance breakdowns. This structure, focusing on a specific, shorter reporting period (quarterly), clearly identifies it as a comprehensive financial report for that period, rather than just an initial earnings release (ER) or a general presentation (IP). Since it is a comprehensive report for a period shorter than a year, the appropriate classification is Interim / Quarterly Report (IR). The document is substantial (19,375 chars) and contains the full results, not just an announcement of the results.
2024-05-15 English
Photocure ASA: Results for the first quarter of 2024
Earnings Release Classification · 100% confidence The document explicitly states it contains "Results for the first quarter of 2024" and provides detailed financial metrics (revenues, EBITDA, EBIT) for that period, along with reiterating financial guidance for the full year 2024. This content structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it presents the key results and highlights immediately, it fits the definition of an Earnings Release (ER). Although it mentions the full financial report and presentation are enclosed/will be published, the primary content provided here is the summary announcement of the quarterly results, making ER the most appropriate classification over IR (which is usually the comprehensive document itself) or RPA (which is just an announcement *about* the report). The document length (6011 chars) is substantial enough to be the release itself, not just a brief announcement wrapper. Q1 2024
2024-05-15 English
Photocure ASA: Results for the first quarter of 2024
Earnings Release Classification · 100% confidence The document explicitly states it contains 'Results for the first quarter of 2024' and provides key financial metrics (revenues, EBITDA) for that period. This strongly indicates a report covering a period shorter than a year. The text mentions 'The quarterly report and presentation will be published...' and provides details about the results. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions a presentation, the core content is the financial results summary, making IR the primary classification over RPA or ER, as it is a comprehensive summary for the period, not just the initial highlights (ER) or just an announcement of publication (RPA). Since the length is substantial (6256 chars) and it contains the actual results, it is the report itself, not just a notice of publication. Q1 2024
2024-05-15 English
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces a specific corporate event: a partner's New Drug Application (NDA) acceptance for regulatory review by the NMPA in China. This is a time-sensitive, material event announcement typical of regulatory or corporate news, but it is not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal proxy/governance document. Since it is a general announcement of a significant regulatory/business development that doesn't fit the highly specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length (4836 chars) is substantial enough to be a full release, not just a brief notification of a report's availability (RPA).
2024-05-12 English
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a 'Press Release' announcing that Photocure's partner, Asieris, has had a New Drug Application (NDA) accepted for regulatory review by the NMPA in China. This type of announcement, detailing progress in drug development, regulatory milestones, or clinical trial results, is typically classified as a general regulatory announcement or a specific corporate update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it concerns a specific regulatory event (NDA acceptance), it fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad announcement of a regulatory event, or potentially a Legal/Regulatory update, but RNS is the most appropriate general catch-all for non-standard regulatory news releases that aren't explicitly covered elsewhere. Given the context of a press release announcing a regulatory milestone, RNS is the most suitable classification.
2024-05-12 English
Photocure ASA: Invitation to presentation of first quarter 2024 financial results
Report Publication Announcement Classification · 98% confidence The document is a short announcement from Photocure ASA regarding the release of its 'first quarter 2024 financial results' scheduled for May 15, 2024. It explicitly states that the 'quarterly report and presentation will be published at 08:00 CEST' and invites stakeholders to a live webcast presentation at 14:00 CEST. Since the document's primary function is to announce the upcoming publication of financial results and provide details for the associated presentation/webcast, it fits the definition of a Report Publication Announcement (RPA). It is not the full Interim Report (IR) itself, nor is it the Earnings Release (ER) which typically contains the key figures, but rather the notice *about* the release.
2024-05-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.